Overview

Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
Phase 3 efficacy and safety of acoramidis in subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Phase:
Phase 3
Details
Lead Sponsor:
Eidos Therapeutics
Eidos Therapeutics, a BridgeBio company